Regulatory framework of the Drug Office, Department of Health and the Pharmacy and Poisons Board

Chapter 2: Regulatory Framework of the Drug Office, Department of Health and the Pharmacy and Poisons Board

Hello, everyone. I am Drew Tang from RGYS. To conduct a pharmaceutical business in Hong Kong, you must first clearly understand the local regulatory structure. This is not only the foundation of compliant operations; RGYS may assist with document preparation and project coordination within the written scope of services; personnel qualifications, statutory roles and professional judgments are to be verified and assumed by the respective responsible parties, and approval is decided independently by the competent authority. Hong Kong's pharmaceutical regulatory system is renowned for its rigour, professionalism and efficiency. It primarily comprises the Drug Office under the Department of Health and the statutory Pharmacy and Poisons Board (PPB). In this chapter, I will analyse the functions, powers and operating models of these two core bodies in detail to help you build a clear regulatory map.

Drug Office, Department of Health (Drug Office) — Guardian of medicine safety in Hong Kong

First, let us discuss the Drug Office. You can think of it as the “operational hub” of medicine regulation in Hong Kong. It is part of the Department of Health and is the principal government department responsible for enforcing key legislation such as the Pharmacy and Poisons Ordinance (Cap. 138) and the Antibiotics Ordinance (Cap. 137). Its work covers the entire lifecycle of medicines, from research and development and manufacture through to sale and use, ensuring the safety, efficacy and quality of all pharmaceutical products on the market.

The Drug Office has a broad range of functions, which can be grouped into several core areas. First, product regulation: all pharmaceutical products sold in Hong Kong, whether locally manufactured or imported, must be registered with it before they can be marketed. Second, licence issuance and management: any organisation or individual wishing to engage in medicine wholesaling, retailing or manufacturing must apply to the Drug Office for the relevant licence. Third, regulatory enforcement and inspections: Drug Office inspectors have statutory powers to conduct regular or unannounced inspections of licensed organisations to ensure that their operations fully comply with legal requirements. Finally, it is responsible for pharmacovigilance and risk communication: it continuously monitors adverse reaction reports for medicines on the market and promptly issues safety information to the public and industry.

Drew Tang's tip: The Drug Office is the body you will deal with most frequently during the licence application process. It leads every stage, from application submission and responses to enquiries to on-site inspections. A thorough understanding of its workflows and approval criteria is therefore important. RGYS may assist with document preparation and project coordination within the written scope of services; personnel qualifications, statutory roles and professional judgments are to be verified and assumed by the respective responsible parties, and approval is decided independently by the competent authority. In my experience, a thoroughly prepared, logically structured application dossier can reduce communication costs during the approval process by at least 30%.

Pharmacy and Poisons Board (PPB) — statutory body responsible for setting rules and standards

If the Drug Office is the enforcer, the Pharmacy and Poisons Board (PPB) is the “legislator” and “judge”. The PPB is a statutory body established under the Pharmacy and Poisons Ordinance (Cap. 138). It is independent and is responsible for advising the Government on the regulation of the pharmaceutical profession, as well as handling pharmacists' registration and disciplinary matters. Its members are appointed by the Government and include experienced pharmacists, doctors, academics and members from outside the industry, ensuring the professionalism and impartiality of its decisions.

The PPB exercises its powers principally through its various committees. For example, the Registration Committee reviews pharmacists' eligibility for registration; only qualified professionals may practise in Hong Kong. The Disciplinary Committee handles complaints against registered pharmacists and may impose disciplinary sanctions; in serious cases, a pharmacist's registration may be revoked. The Manufacturers Licensing Committee and other committees focus on setting licensing approval standards in specific areas. Together, these committees form the PPB's decision-making system, ensuring professional and ethical standards across the industry.

Cross-agency collaboration and regulation of Chinese medicine

Hong Kong’s medicine regulatory system covers more than western medicines. Since the Chinese Medicine Ordinance (Cap. 549) came into effect, the regulation of Chinese medicine has also been systematised. The Chinese Medicine Regulatory Office (CMRO), which is also under the Department of Health, administers the Ordinance. Its functions are similar to those of the Drug Office but focus on the registration of Chinese herbal medicines and proprietary Chinese medicines, regulation of practitioners, and licence management.

Although day-to-day implementation for Western and Chinese medicines is handled by different offices, their regulatory policies are coordinated at a higher level. For example, some products containing both Western and Chinese medicine ingredients must meet the regulatory requirements of both bodies. This model combines a division of responsibilities with coordination, ensuring comprehensive coverage of all types of medicines. The table below clearly compares the core functions of the principal regulators: